secwatch.observer — SEC 8-K summary
======================================

Issuer:     Protara Therapeutics, Inc. (TARA)
CIK:        0001359931
Form:       8-K
Filed at:   2025-06-12T23:59:59+00:00
Accession:  0001213900-25-053844
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud

Protara Therapeutics stockholders elect directors and approve equity plan at 2025 annual meeting
--------------------------------------------------------------------------------

- Stockholders elected Luke Beshar, Roger Garceau, and Gregory Sargen as Class II directors with 17.7M, 22.1M, and 22.1M votes for, respectively.
- Ratification of Ernst & Young as independent auditor for fiscal 2025 was approved with 29.3M votes for, 147,664 against, 327,362 abstentions.
- Advisory vote on executive compensation passed with 20.4M for, 134,110 against, 2.1M abstentions, and 7.2M broker non-votes.
- Amendment to the 2024 Equity Incentive Plan was approved with 21.3M for, 907,425 against, 365,697 abstentions, and 7.2M broker non-votes.
- Over 38.5M shares were outstanding as of the April 16, 2025 record date; meeting held June 11, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1359931/000121390025053844/0001213900-25-053844-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1359931/000121390025053844/ea0245492-8k_protara.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-053844

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer